O. Molinier

558 total citations
20 papers, 296 citations indexed

About

O. Molinier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, O. Molinier has authored 20 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in O. Molinier's work include Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). O. Molinier is often cited by papers focused on Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). O. Molinier collaborates with scholars based in France, Spain and Germany. O. Molinier's co-authors include Saulius Cicėnas, Giuseppe Giaccone, A. Szczęsna, Tudor–Eliade Ciuleanu, Federico Cappuzzo, Gaëlle Klingelschmitt, Jean-Louis Pujol, Symantha Melemed, Eckart Laack and Nadia Chouaki and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

O. Molinier

19 papers receiving 282 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O. Molinier France 9 247 216 39 26 24 20 296
Masafumi Sata Japan 10 194 0.8× 202 0.9× 51 1.3× 20 0.8× 12 0.5× 25 283
J.-S. Lee South Korea 7 200 0.8× 268 1.2× 66 1.7× 44 1.7× 37 1.5× 17 310
Carlos Mayo United States 9 151 0.6× 164 0.8× 75 1.9× 12 0.5× 41 1.7× 16 254
Margaux Geier France 8 150 0.6× 167 0.8× 23 0.6× 26 1.0× 17 0.7× 41 220
Yujia Chi China 11 125 0.5× 110 0.5× 41 1.1× 39 1.5× 21 0.9× 20 209
Izidor Kern Slovenia 10 242 1.0× 124 0.6× 32 0.8× 6 0.2× 39 1.6× 23 290
Christian Boch Germany 3 110 0.4× 95 0.4× 43 1.1× 19 0.7× 44 1.8× 4 149
L Morrissey United States 3 130 0.5× 113 0.5× 121 3.1× 13 0.5× 49 2.0× 4 248
Kenji Akie Japan 8 134 0.5× 182 0.8× 100 2.6× 38 1.5× 36 1.5× 9 250
Marie-Paule Lebitasy France 8 242 1.0× 174 0.8× 17 0.4× 45 1.7× 27 1.1× 13 285

Countries citing papers authored by O. Molinier

Since Specialization
Citations

This map shows the geographic impact of O. Molinier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Molinier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Molinier more than expected).

Fields of papers citing papers by O. Molinier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. Molinier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Molinier. The network helps show where O. Molinier may publish in the future.

Co-authorship network of co-authors of O. Molinier

This figure shows the co-authorship network connecting the top 25 collaborators of O. Molinier. A scholar is included among the top collaborators of O. Molinier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. Molinier. O. Molinier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mascaux, Céline, Laurent Greillier, L. Moreau, et al.. (2025). OA05.02 First-Line Atezolizumab Plus Chemotherapy in Elderly Patients With Advanced NSCLC, IFCT-1805 Elderly: A Randomized, Multicenter, Phase 3 Trial. Journal of Thoracic Oncology. 20(10). S19–S19.
2.
Molinier, O., J. Pinsolle, Sebastian Schneider, et al.. (2024). COVID-19 among lung cancer patients: Data from a real-life prospective French multicentric study. Respiratory Medicine and Research. 86. 101093–101093. 1 indexed citations
3.
Molinier, O., I. Monnet, C. Decroisette, et al.. (2022). 509P COVID-19 disease among lung cancer (LC) patients: Data from a real-life prospective multicentric study. Annals of Oncology. 33. S775–S776. 1 indexed citations
4.
5.
Peters, Solange, J.L. Pujol, Urania Dafni, et al.. (2020). LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial. Annals of Oncology. 31. S1211–S1211. 12 indexed citations
6.
Zalcman, Gérard, Julien Mazières, Laurent Greillier, et al.. (2019). Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD). Annals of Oncology. 30. v747–v747. 16 indexed citations
7.
8.
Pujol, Jean-Louis, Laurent Greillier, Clarisse Audigier-Valette, et al.. (2018). A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial. Annals of Oncology. 29. viii596–viii596. 9 indexed citations
9.
Domblides, Charlotte, I. Monnet, Julien Mazières, et al.. (2018). Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort. Annals of Oncology. 29. viii406–viii406. 8 indexed citations
10.
11.
Besse, Benjamin, Julien Mazières, Laureen Ribassin-Majed, et al.. (2015). Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703.. Journal of Clinical Oncology. 33(15_suppl). 7510–7510. 1 indexed citations
12.
Zalcman, Gérard, Julien Mazières, J. Margery, et al.. (2015). Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.. Journal of Clinical Oncology. 33(15_suppl). 7500–7500. 20 indexed citations
13.
Pujol, Jean-Louis, A. Lavolé, B. Mennecier, et al.. (2014). Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial.. Journal of Clinical Oncology. 32(15_suppl). 7505–7505. 3 indexed citations
14.
Moro‐Sibilot, Denis, Clarisse Audigier-Valette, P. Merle, et al.. (2013). Comparison of two chemotherapy regimens in non-small cell lung cancer patients relapsing after surgery and peri-operative chemotherapy (IFCT-0702 study).. Journal of Clinical Oncology. 31(15_suppl). 8081–8081. 1 indexed citations
15.
16.
17.
Zalcman, Gérard, Julien Mazières, Arnaud Scherpereel, et al.. (2012). IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology. 30(15_suppl). TPS7112–TPS7112. 18 indexed citations
18.
Paris, Adeline, et al.. (2011). Pneumopathie médicamenteuse sous sirolimus : interaction avec l’atorvastatine ?. Revue des Maladies Respiratoires. 29(1). 64–69. 2 indexed citations
19.
20.
Cappuzzo, Federico, Tudor–Eliade Ciuleanu, Saulius Cicėnas, et al.. (2009). SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. Journal of Clinical Oncology. 27(15_suppl). 8001–8001. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masafumi Sata Breakdown of academic impact, for papers by J.-S. Lee Breakdown of academic impact, for papers by Carlos Mayo Breakdown of academic impact, for papers by Margaux Geier Breakdown of academic impact, for papers by Yujia Chi Breakdown of academic impact, for papers by Izidor Kern Breakdown of academic impact, for papers by Christian Boch Breakdown of academic impact, for papers by L Morrissey Breakdown of academic impact, for papers by Kenji Akie Breakdown of academic impact, for papers by Marie-Paule Lebitasy
Rankless by CCL
2026